Table 2 Representative stem cell trials and designed research for PD and some other neurodegenerative disease in patients
From: Mesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptoms
Potential bio-therapy intervention | Study design information | ||
|---|---|---|---|
Cell source | Delivery path | Treatment number/test(s) | Report year(s) |
Embryonic dopamine cell | Implant surgery | Total 34 cases/(NCT00038116) | 2001–2009 |
ESC-derived A9 dopamine progenitor cell | Administration of the putamen into the brain (~ 106) | Twelve patients/(NCT05887466) | 2001–2023 |
Autologous adipose tissue-derived stromal vascular fraction | Subdermal plane injection (~ 107) | Ten patients/inflammatory biomarkers at 12-month follow-up (NCT05699161) | 2009–2020 |
ESC-derived neural precursor cell | Striatal implantation | Total 50 cases/(NCT03119636) | 2018 |
RC17 ventral midbrain dopaminergic progenitor cell | Surgical implantation (106–107/six tracks) | Eight patients/HLA class I detection (NCT05635409) | 1989–2020 |
Autologous peripheral nerve graft | Unilateral implantation into the substantia nigra | Eight patients/deep brain stimulation therapy reduction (NCT01833364) | 2016–2018 |
Neural stem cell | Nasal cavity delivery (106/week) | Twelve patients/(NCT03128450) | 2013–2014 |
Autologous peripheral nerve graft | Implantation into the substantia nigra, basal forebrain, putamen with/o STN-DBS | ~ 70 patients/DaTscan SPECT imaging assessment at up to 24-month follow-up (NCT02369003) [9] | 2005–2022 |
Parthenogenetic neural stem cell | Intracerebral injection into striatum and substantia nigra | Twelve patients/(NCT02452723) | 2016–2018 |
Autologous adipose-derived MSC | Intravenous injection | ~ 30 patients/(NCT04995081) | 2005–2020 |
Bone marrow-derived MSC | Intravenous injection | Twenty patients/(NCT01446614) | 2007–2010 |
Allogeneic bone marrow-derived MSC | Infusions (107/kg) | Thirty cases/(NCT04506073) | 1996–2018 |
Autologous MSC | Intravenous intervention | Thirty patients/(NCT04146519) | 2020 |
Autologous bone marrow-derived MSC | Intravenous route and intranasal route into inferior nasal conchas and meatuses | ~ 500 patients/(NCT02795052) | 2011–2016 |
Topical bone marrow-derived MSC fraction | Intravenous and intranasal routes (14 cc and 1 cc) | ~ 100 patients/(NCT03724136) | 2009–2018 |
Autologous adipose-derived tissue stromal vascular fraction | Intravenous parenteral route (500 cc) | ~ 300 patients/(NCT03297177) | 1988–2015 |